4 results
8-K
EX-99.2
LBPH
Longboard Pharmaceuticals Inc
12 Mar 24
Longboard Pharmaceuticals Reports Full Year 2023 Financial Results and Provides Corporate Updates
4:10pm
Scientific Rationale Commercial & Development Criteria Etiology Pathophysiology Approved SoC Preclinical Studies Patient Advocacy & Recruitment Degree
8-K
EX-99.1
LBPH
Longboard Pharmaceuticals Inc
29 Nov 23
Regulation FD Disclosure
8:35am
Preclinical Studies Patient Advocacy & Recruitment Degree of Unmet Need Speed of Clinical Development Clinical Trial Feasibility Competitive Headroom
8-K
EX-99.1
LBPH
Longboard Pharmaceuticals Inc
3 Nov 22
Longboard Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2022 Financial Results
8:46am
and diagnostic review training in order to facilitate recruitment,” stated Kevin R. Lind, Longboard’s President and Chief Executive Officer. “For LP659
8-K
EX-99.1
LBPH
Longboard Pharmaceuticals Inc
4 Aug 22
Longboard Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2022 Financial Results
4:19pm
half of 2023 by focusing our efforts on site activation and recruitment, including the planned expansion into Australia and the Australian Epilepsy
- Prev
- 1
- Next